Unlock instant, AI-driven research and patent intelligence for your innovation.

Kras g12c inhibitors

An alkyl and heteroaryl technology, applied in the field of compounds that inhibit KRasG12C, can solve problems such as the safety and/or efficacy of KRas inhibitors

Pending Publication Date: 2020-11-24
MIRATI THERAPEUTICS INC +1
View PDF6 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite three decades of massive discovery efforts to develop KRas inhibitors for the treatment of cancer, no KRas inhibitor has demonstrated sufficient safety and / or efficacy to obtain regulatory approval (see, for example, McCormick (2015) "Clinical Cancer Research" 21(8):1797-1801)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kras g12c inhibitors
  • Kras g12c inhibitors
  • Kras g12c inhibitors

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0537] The following intermediates were prepared according to the method for the preparation of intermediate 3, substituting the appropriate phenol for 2-bromo-3-fluorophenol.

[0538]

[0539] Intermediate 44

[0540]

[0541] 2-Bromo-3-fluoro-1-(methoxymethoxy)-4-methylbenzene

[0542] Step 1: Put 3-fluoro-4-methylphenol (1.016g, 8.055mmol) into Cs 2(3.9 mL, 64.44 mmol) and cooled to 0°C. Add Br 2 (0.4150 mL, 8.055 mmol) and the mixture was stirred at room temperature for 2 hours. Add 10% Na 2 S 2 o 2 And the mixture was extracted with DCM. The organic layers were combined, dried and filtered to give 2-bromo-3-fluoro-4-methylphenol (1.389 g, 6.775 mmol, 84.10% yield), which was used directly in the next step.

[0543] Step 2: 2-Bromo-3-fluoro-1-(methoxymethoxy)-4-methylbenzene was according to the procedure for Intermediate 8 using 2-bromo-3-fluoro-4-methylphenol Prepared instead of 2-bromo-3-fluorophenol.

[0544] Intermediate 45

[0545]

[0546] 2-Brom...

Embodiment 1

[0724]

[0725] 1-(4-(7-(3-Hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl ) prop-2-en-1-one

[0726]

[0727] Step A: 4-(4-((Benzyloxy)carbonyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7 (6H)-tert-butyl formate: Combine tert-butyl 4-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.0 g, 3.7 mmol), triethylamine in 2 mL of dimethylacetamide (1.0 mL, 7.4 mmol) and benzyl 1-piperazinecarboxylate (0.86 mL, 4.4 mmol). The reaction vessel was sealed and the reaction mixture was heated to 90°C with stirring. After 5 hours, the reaction was diluted with brine and extracted with methyl tert-butyl ether. The combined organic layers were washed sequentially with saturated ammonium chloride and brine, washed over MgSO 4 Drying and concentration under reduced pressure gave a thick oil. The oil was carried out chromatographic separation ( 24 g), eluted with 1:1 ethyl acetate / hexane to give 4-(4-((benzyloxy)carbonyl...

Embodiment 2

[0735]

[0736] 1-(4-(7-(7-Hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl ) prop-2-en-1-one

[0737] According to the method of Example 1, in step C, 2-bromo-7-(methoxymethoxy)naphthalene was used instead of 1-bromo-3-(methoxymethoxy)naphthalene for synthesis. ES+APCI MS m / z 416.1[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Description

technical field [0001] The present invention relates to compounds which inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRasG12C, pharmaceutical compositions comprising said compounds, and methods of use thereof. Background technique [0002] Kirsten rat sarcoma 2 viral oncogene homolog ("KRas") is a small GTPase and a member of the Ras oncogene family. KRas acts as a molecular switch that cycles between an inactive state (GDP-bound) and an active state (GTP-bound) to transduce upstream cellular signals received from various tyrosine kinases to downstream effectors, by This regulates a variety of processes, including cell proliferation (see eg Alamgeer et al. (2013), Current Opin Pharmacol. 13:394-401). [0003] The role of activated KRas in malignant disease was observed more than three decades ago (see, eg, Santos et al. (1984), Science 223:661-664). Aberrant expression of KRas accounts for 20% of al...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/06C07D401/14
CPCC07D471/04A61P35/00C07D491/08A61K31/5377A61K31/519A61K31/5355
Inventor 詹姆斯·F·布莱克劳伦斯·E·伯吉斯马克·约瑟夫·希凯利詹姆斯·盖尔·克里斯滕森亚当·库克杰伊·布拉德福德·费尔约翰·P·费舍尔马修·阿诺德·马克思马塞多尼奥·J·梅西亚帕维尔·萨瓦钦科夫盖伊·P·A·威格士克里斯多夫·罗纳德·史密斯玛莎·E·罗德里格斯
Owner MIRATI THERAPEUTICS INC